BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33993536)

  • 21. [Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis].
    Zheng LL; Li B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1108-1112. PubMed ID: 37551484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients.
    Jew S; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Spektor TM; Berenson JR
    Br J Haematol; 2021 Mar; 192(6):1064-1067. PubMed ID: 32321191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
    Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
    Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement.
    Lin Z; Yu N; Cheng C; Jin B; Zhang Q; Zhuang H; Jiang X
    Lupus; 2023 Apr; 32(5):680-687. PubMed ID: 36914971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.
    Maglione PJ; Ko HM; Tokuyama M; Gyimesi G; Soof C; Li M; Sanchez E; Chen H; Radigan L; Berenson J; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):283-291.e1. PubMed ID: 31430592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
    Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
    Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
    Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
    Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
    Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
    Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.
    Evliyaoglu O; van Helden J; Jaruschewski S; Imöhl M; Weiskirchen R
    Clin Biochem; 2019 Dec; 74():42-46. PubMed ID: 31526775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
    Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C
    Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
    Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
    Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
    Rajkumar SV; Bergsagel PL; Kumar S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
    Hájek R; Sandecka V; Špička I; Raab M; Goldschmidt H; Beck S; Minařík J; Pavlíček P; Radocha J; Heindorfer A; Jelínek T; Stejskal L; Brožová L; Ševčíková S; Straub J; Pika T; Pour L; Maisnar V; Seckinger A; Hose D
    Br J Haematol; 2020 Jul; 190(2):189-197. PubMed ID: 32163180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.